Middle East & Africa Infectious Disease Therapeutics Market
The Middle East & Africa Infectious Disease Therapeutics Market size was valued at US$ 5,722.81 Mn in 2022 and is projected to reach US$ 7,237.61 Mn by 2030, growing at a CAGR of 3.0% during 2022 - 2030.
Report Coverage
- Drug Class: Anti-viral, Anti-Bacterial, Anti-Fungal
- Indication: HIV, Hepatitis, Tuberculosis, Influenza, HPV
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies
US$ 5,722.81 Mn
Market size in 2022
US$ 7,237.61 Mn
Market Size by 2030
3.0%
CAGR, 2022 - 2030
2023-2030
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Middle East & Africa Infectious Disease Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Middle East & Africa Infectious Disease Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Middle East & Africa Infectious Disease Therapeutics Market Regional Analysis
6.2 Middle East & Africa Infectious Disease Therapeutics Market Revenue 2020-2030 (US$ Million)
6.3 Middle East & Africa Infectious Disease Therapeutics Market Forecast Analysis
7. Middle East & Africa Infectious Disease Therapeutics Market Analysis – by Drug Class
7.1 Anti-viral
- 7.1.1 Overview
- 7.1.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Anti-Bacterial
- 7.2.1 Overview
- 7.2.2 Anti-Bacterial: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.3 Anti-Fungal
- 7.3.1 Overview
- 7.3.2 Anti-Fungal: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. Middle East & Africa Infectious Disease Therapeutics Market Analysis – by Indication
8.1 HIV
- 8.1.1 Overview
- 8.1.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Hepatitis
- 8.2.1 Overview
- 8.2.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.3 Tuberculosis
- 8.3.1 Overview
- 8.3.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.4 Influenza
- 8.4.1 Overview
- 8.4.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.5 HPV
- 8.5.1 Overview
- 8.5.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. Middle East & Africa Infectious Disease Therapeutics Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
10. Middle East & Africa Infectious Disease Therapeutics Market – Middle East and Africa Analysis
10.1 Overview
10.2 Middle East and Africa- 10.2.1 Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Key Country, 2023 and 2030 (%)
- 10.2.1.1 Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 South Africa: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.1.1 South Africa: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.1.2 South Africa: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.1.3 South Africa: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.2 Saudi Arabia: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.2.1 Saudi Arabia: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.2.2 Saudi Arabia: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.2.3 Saudi Arabia: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.3 UAE: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.3.1 UAE: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.3.2 UAE: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.3.3 UAE: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.4 Rest of Middle East and Africa: Middle East & Africa Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.4.1 Rest of Middle East and Africa: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.4.2 Rest of Middle East and Africa: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.4.3 Rest of Middle East and Africa: Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 AbbVie Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Astellas Pharma Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bayer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Gilead Sciences Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GSK Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Merck & Co Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full M Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
